• HOME>
  • Investor Relations>
  • IR News>
  • Sumitomo Pharma Selected for Inclusion as a Constituent of Five GPIF-Adopted ESG Indexes that Cover Japanese Stocks

IR News

Aug. 31, 2022Print(PDF/477KB)Sustainability

Sumitomo Pharma Selected for Inclusion as a Constituent of Five GPIF-Adopted ESG Indexes that Cover Japanese Stocks

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) announced today that it has been selected for inclusion as a constituent in all the ESG indexes that cover Japanese stocks adopted by the Government Pension Investment Fund (GPIF).

The five indexes in which the Company was selected for inclusion as a constituent are the FTSE Blossom Japan Index, the FTSE Blossom Japan Sector Relative Index, the MSCI Japan ESG Select Leaders Index, the MSCI Japan Empowering Women Index (WIN), and the S&P/JPX Carbon Efficient Index.

In addition to the above indexes adopted by GPIF, Sumitomo Pharma has been selected for inclusion (as a constituent) in the FTSE4Good Index Series, a leading ESG investment index, for 20 consecutive years since 2003.

Corporate Mission of Sumitomo Pharma is "To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide." Sumitomo Pharma defines the implementation of this Corporate Mission as "CSR-Based Management." Sumitomo Pharma will continue to promote CSR-based management and aim at the sustained enhancement of corporate value.

* For Initiatives of CSR-based management and sustainability of Sumitomo Pharma and external evaluation, please visit:
https://www.sumitomo-pharma.com/sustainability

Reference
About five ESG indexes that cover Japanese stocks adopted by GPIF
■ FTSE Blossom Japan Index
The FTSE Blossom Japan Index is created by the global index provider FTSE Russell (U.K.) to measure the performance of Japanese companies demonstrating strong Environmental, Social and Governance (ESG) practices. Sumitomo Pharma has been continuously included as a constituent in the Index since 2017 when the Index was launched.

■ FTSE Blossom Japan Sector Relative Index
The FTSE Blossom Japan Sector Relative Index is created by the global index provider FTSE Russell (U.K.) to measure the performance of Japanese companies demonstrating strong Environmental, Social and Governance (ESG) practices in each sector. Sumitomo Pharma has been continuously included as a constituent in the Index since 2022 when the Index was launched.

■ MSCI Japan ESG Select Leaders Index
The MSCI Japan ESG Select Leaders Index targets 50% of the free float-adjusted market capitalization of each Global Industry Classification Standard (GICS®) Sector and is designed to target companies that have high Environmental, Social and Governance (ESG) performance. Sumitomo Pharma has been continuously included as a constituent in the Index since 2017 when the Index was launched.

■ MSCI Japan Empowering Women Index (WIN)
The MSCI Japan Empowering Women Index (WIN) aims to represent the performance of companies that are leading within their GICS® sector groups in terms of promoting and maintaining gender diversity while also meeting certain quality factor criteria. Sumitomo Pharma included as a constituent in the Index in 2017, 2019, 2020, 2021 and 2022.

■ S&P/JPX Carbon Efficient Index
The S&P/JPX Carbon Efficient Index is an ESG index jointly designed by S&P Dow Jones Indices and Japan Exchange Group. This index comprises companies included in the Tokyo Stock Price Index (TOPIX), and the weight of constituent is determined by carbon efficiency (Carbon emissions per unit of revenue) and the disclosure status of environmental information. Sumitomo Pharma is evaluated as the carbon efficiency decile classification is "2", and the carbon disclosure status is "Disclosed."

About FTSE4Good Index Series
The FTSE4Good Index Series is created by the global index provider FTSE Russell (U.K.) to measure the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices. Transparent management and clearly-defined ESG criteria make FTSE4Good indexes suitable tools to be used by a wide variety of market participants when creating or assessing sustainable investment products. Sumitomo Pharma has been continuously included as a constituent in the Index series since 2003.